Nyrada Inc
NYR
Company Profile
Business description
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
Contact
828 Pacific Highway
Suite 2, Level 3
GordonNSW2072
AUST: +61 294983390
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,175.10 | 49.90 | 0.61% |
CAC 40 | 7,536.26 | 33.48 | 0.45% |
DAX 40 | 22,242.45 | 177.94 | 0.81% |
Dow JONES (US) | 40,113.50 | 20.10 | 0.05% |
FTSE 100 | 8,415.25 | 7.81 | 0.09% |
HKSE | 21,980.74 | 70.98 | 0.32% |
NASDAQ | 17,382.94 | 216.90 | 1.26% |
Nikkei 225 | 35,705.74 | 666.59 | 1.90% |
NZX 50 Index | 12,017.84 | 61.37 | 0.51% |
S&P 500 | 5,525.21 | 40.44 | 0.74% |
S&P/ASX 200 | 7,968.20 | 47.70 | 0.60% |
SSE Composite Index | 3,295.06 | 2.23 | -0.07% |